A Phase 1 Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Status:
Not yet recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
This is a first-in-human dose escalation and cohort expansion multicenter, open-label study
designed to evaluate the safety and preliminary efficacy of NX-5948 in patients with advanced
B-cell malignancies.